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ABSTRACT 
Identification of a human subject into a study for a clinical trial involves screening and placebo run in periods. In some cases additional 
screening process is required as some therapeutic agents will be effective in patients with some disorders as they show changes in response. 
Hence, an additional screening process called Enrichment design is employed in the clinical trials which includes active treatments as it helps in 
easy identification of patients in whom test agents are found to be beneficial during early phase of trial. They also helps in identification of 
patients with better therapeutic response. Thus, this additional screening process restricts the target population into a very small selective 
group during the clinical trial making the trial process easier and effective. 
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INTRODUCTION 
 In clinical trials, the inclusion and exclusion criteria define 
the target population. So in order to identify the eligible 
subjects, a screening period is done before enrolling the 
subjects into the study. After screening period placebo-run 
period is performed before the double blind, randomized, 
active treatment period to know the compliance of patients 
and also to estimate the potential placebo effect. Thus, 
screening and placebo run in periods are used as sequential 
screening processes to select the subjects who meet both 
inclusion/exclusion and compliance criteria, when active 
treatment is not given during investigation to patients. 
Evaluation of pharmaceuticals or treatments based on hard 
efficiency endpoints which include death, myocardial 
infarction, or bone fracture is the main objective of some 
trials. But these hard end points require a long period follow 
up for observation. But in contrast short term response for 
soft end points i.e biomarkers are obtained much more 
quickly. In some cases, therapeutic agents are found to be 
effective in patients with underlying disorder that shows 
responses to the manipulation of dose levels or a single 
agent or several agents. Therefore, after screening period or 
placebo run period it is necessary to perform additional 
screening processes which include active treatments as it 
helps in easy identification of patients in whom test agents 
are found beneficial during the early phase of trial. These 
agents are found beneficial during the early phase of trial. 
This additional phase of screening process using some 
therapeutic agent or test or different agents is called 
enrichment phase which helps in identification of patients 
with drug efficacy. Such patients showing drug efficacy are 
then randomised so that they receive either the efficacious 
dose (reagent) or the matched placebo or the active controls. 
Thus the enrichment design is defined as a type of design 
that includes additional screening processes with active 
treatments that are evaluated in the study[1]. Thus based on 
the definition the active treatments used to identify the 
patients are the differences between both screening or 
placebo run periods and the enrichment designs. 
EXAMPLES 
Enrichment design consists of 2 phases. The first phase is 
called enrichment phase in which patients are classified into 
groups based on the benefits obtained from pharmaceuticals 
using titration design. The second phase is called 
randomised double-blind phase conducted with placebo 
concurrent control so as to investigate formally and 
rigorously the effectiveness and safety of test agents in 
patients. During the evaluation of the two phases of an 
enrichment depending upon the objectives of the trial some 
or different primary efficacy end points are used. In three 
clinical trials in the areas of Alzheimer’s disease and 
arrhythmia that is described by Chow and Liu[2] illustrates 
the enrichment design. 
During the early development stage of tacrine, with doses of 
40mg and 80mg, 4 times a day that is used in the treatment 
of Alzheimer’s disease, enrichment design is elected for the 
clinical trial. According to Davis et al[3] all patients with 
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Alzheimer’s disease will respond to any single treatment due 
to clinical, biochemical and pathological heterogeneity as 
well as clinical experience. If some patients respond then 
they show response only within a limited dose range. Thus 
enrichment design is selected during these situations. 
The above clinical trial consists of 4 phases: six-week 
double-blind dose titration enrichment phase, a two week 
placebo baseline phase, a six week randomised double blind 
placebo controlled phase, and a six week sustained phase. 
Then patients who meet the inclusion and exclusion criteria 
are then enrolled into enrichment phase trial that consists of 
3 two-week dosing periods. The dose in each titration 
sequence is titrated up from 40-80mg 4 times a day with 
placebo in dosing periods 1, 2, 3 for titration sequences 1, 2, 
3 respectively. The patients are then randomised into one of 
the three titration sequences conducted in a double blind 
fashion. The therapeutic responses for each patient at each 
dose are then accessed at the end of two-week dosing 
period. The best dose response for a patient was defined in 
advance in protocol as a reduction of atleast 4 points from 
the screening value in a total score on the Alzheimer's 
Disease Assessment Scale (ADAS) [4] and without intolerence 
side effects. Patients who are identified with "best dose" are 
then made to enter into a two week placebo baseline period 
with the hope that this period will be successfully long for 
tacrine to washout from the body and for the patients to 
return to screening pretreatment status with outcomes that 
are comparably effecient. 
At the end of two week placebo baseline phase, if the 
patients points are reduced atleast by 4 in ADAS during 
enrichment phase then they are entered into subsequent 6 
week randomised double-blind, parallel group, placebo 
controlled phase. Here the patients are randomised either to 
the active tacrine at their best dose or to the placebo that 
matches. Then the patients after completing the 6-week 
double blind phase, then they are entered into the sustained 
active treatment phase. Thus identification of a group of 
people who are likely to respond to tacrine at certain dose is 
done by the selection of an enrichment design with three 
titration sequences. These identified patients after washout 
period of 2 weeks are then further randomised to either 
tacrine at their best dose or to the placebo concurrent 
control in a double blind phase. 
In the development of tacrine the main reason for selection 
of the enrichment design is to verify whether a short term 
response to tacrine has predictability for the long term 
efficacy in the prevention of progression of the patients with 
probable Alzheimer's disease. The same primary efficacy 
end points such as ADAS or the Clinical Global Impression of 
Change were used in both the enrichment and double blind 
phases for the evaluation of effectiveness of tacrine. 
On the other hand for other therapeutic agents, the real 
efficacy endpoint is mortality that requires along time for 
observation. So short term efficacy of the agents is accessed 
by some other objective surrogate end points. Then it is 
important to know whether the short term efficacy based on 
surrogate end point is predictive of the hard point such as 
mortality. Therefore enrichment design is usually employed 
for the identification of the short term responders at initial 
stage followed by the main phase of long term study. 
Examples of this type of trials can be found in the area of 
Arrhythmia such as Cardiac Arrhythmia Suppression Trial 
(CAST) [5-7] and Electrophysiologic Study Versus 
Electrocardiogarhic Monitoring (ESVEM)[8-12]. 
Cardiac Arrhythmia Suppression Trial is a multi center, 
randomised, placebo controlled study that is used to test 
whether the suppression of asymptomatic or mildly 
symptomatic ventricular arrhythmic agents, ecainide and 
flecainide and with a placebo concurrent control. The 
objective of the study is to test the predictability of adequate 
suppression of ventricular arrhythmia by the active drugs 
based on Ventricular Premature Contractions (VPC) as 
recorded by Hotter monitor for mortality. As a result, an 
open model enrichment design with 2 titration sequences 
involving only active drugs is selected for this study. Patients 
with ejection fraction of atleast 30% are randomly assigned 
to the two titration sequences. (encainide, moricizine, 
flecainide) or (flecainide,moricizine,ecainide). Morcizine has 
inferior efficacy in the suppression of VPC in comparison 
with other 2 agents hence it is inserted in the middle dosing 
period. Each drug is tested at 2 dose levels. The doses are 35 
and 50 mg 3 times a day for ecainide, 100 and 150 mg twice 
a day for flecainide, 200 and 250mg t.i.d for moricizine. 
Flecainide is not administered to the patients who have an 
ejection fraction of less than 30% because it exhibits 
negative inotropic properties. In patients with ejection 
fraction of less than 30% the titration sequences are 
(encainide, moricizine) or (moricizine, ecainide). The 
prespecified criteria for an adequate suppression of 
ventricular arrhythmia are 
i. Reduction of 80% in VPC 
ii. Reduction of atleast 90% runs of unsustained ventricular 
tachycardia as measured by 24 hour Holter recording for 
4-10 days after each dose began. The titration process 
for a particular patient is stopped as soon a drug and 
dose are found to yield an adequate supression. Then, 
the patients whose arrhythmia is adequately suppressed 
are then randomised to either best drug identified 
during enrichment phase or to placebo for 3 year long 
term followup. 
The results of CAST indicates the short term efficacy 
measured as supression of VPC based on Holter non invasive 
ambulatory electrocardiograhic monitoring might not be a 
good predictor for the long term hard mortality endpoint. 
The good independent predictor of recurrence of arrhythmia 
in the failure to induce ventricular tachycardia or fibrillation 
by some drug accessed by the invasive electrophysiologic 
study. The EVSEM trial is the first large prospective, 
randomised trial conducted to compare the 2 methods as it 
requires correlating the difference in reccurance rates of 
arrhythmia with the short term efficacy by both methods, an 
in-patient enrichment phase which is selected to identify a 
group of patients in whom the test drug exhibits a short 
term efficacy accessed by either one of the 2 methods. After 
the patients fulfill their entry criteria and 48 hour Houlter 
monitoring and electrophysiologic groups for the 2 methods 
to access the short term drug efficacy. 
The first group employed is non invasive ambulatory 
electrocardiograhic monitoring while the second group 
applied is the invasive electrophysiologic study. Then in each 
group the patients receive up to 6 arrhythmia agents in a 
random order until one drug is predicted to be efficacious or 
until all drugs have been tried that the patients were eligible 
to receive. A test drug is identified as effective as accessed by 
electrocardiograhic monitoring the inpatient enrichment 
phase which is defined as the failure by the drug to induce a 
run of ventricular tachycardia longer than 15 seconds with 
V2, and V3 stimulation at the right ventricular apex. 
If a drug should be proved efficient for a patient during the 
enrichment phase then that patient is discharged from the 
hospital for the long term follow-up with the drug and the 
accuracy of the prediction of efficacy is determined during 
Santosh Kumar et al                                                                                         Journal of Drug Delivery & Therapeutics. 2019; 9(4-s):803-805 
ISSN: 2250-1177                                                                                  [805]                                                                                 CODEN (USA): JDDTAO 
the long term follow-up. Patients in whom no drugs are 
proven to be effective and are not randomized but 
withdrawn from the study. Enrichment design can also be 
used for the studies in non responders or in patients 
intolerant of another agent. Temple provided examples in 
studies for severe hypertension and psychotropic agents. 
The disease targets at molecular level can be identified after 
completion of Human Genome Project (HGP). Hence 
treatment modalities that are specific to patients with their 
identified molecular targets are evaluated in targeted clinical 
trials. Only the patients who are tested positive for 
molecular targets are enrolled and randomized into the 
targeted clinical trials, enrichment design for targeted 
clinical trials. Examples are ALITO trials [13], TAILORX 
trials[14] and MINOACT trial[15]. Simon and Maitournam [16] 
and Maitournam and Simon[17] have discussed requirement 
of sample sizes between the targeted clinical trials versus 
untargeted trials.In addition to it Liu and Lin[18] and Liu et 
al[19] have suggested the use of EM logarithm for statistical 
inference of treatment effects for targeted clinical trials 
under enrichment. 
CONCLUSION  
Screening for possible responders using the active 
treatments under investigation is the main objective of an 
enrichment design. However, placebo responders will also 
be identified in the enrichment phase if placebo is also 
included in the enrichment phase. A dose titration designs 
with no washout periods is the design employed in the 
enrichment phase.  As a result during the process of 
identification of responders the treatment effects, carryover 
effects, and time effects all confound one another. As soon as 
the first drug is found to yield an adequate suppression of 
VPC at the first dose the patients are randomized in CAST or 
ESVEM. Another issue for enrichment design is that whether 
the response observed is the best drug at optimal dose for 
the responder or not. on the other hand statistical methods 
used for analysis which are based on the data from both the 
enrichment phases and the double blind phase of the trail 
are not fully developed because of lack of randomization or 
different methods of randomization for the enrichment 
design, statistical methods for analysis. In summary, 
restriction of target population into very small selective 
groups is done by enrichment design. However 
distinguishing this small group of patients from rest who are 
with same alignment in terms of demographic and other 
prognostic factors for grassroots clinical practice is not 
possible sometimes. Therefore, the inferences obtained from 
the trials using enrichment design from statistical analysis 
remains as a challenge. 
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